Silo Pharma (SILO) Cash & Equivalents (2010 - 2026)

Silo Pharma has reported Cash & Equivalents for 14 years, with the latest figure at $3.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 24.41% year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 24.41% YoY) and the FY2025 annual result came in at $4.7 million, up 21.58% from the prior year.
• Cash & Equivalents retreated to $3.9 million in Q1 2026 per SILO's latest filing, from $4.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $12.3 million in Q3 2022 and troughed at $158832.0 in Q2 2023.
• A 5-year average of $5.1 million and a median of $4.3 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 98.37% in 2023, then jumped 2737.15% in 2024.
• Over 5 years, Cash & Equivalents stood at $11.4 million in 2022, then plunged by 69.0% to $3.5 million in 2023, then gained by 10.82% to $3.9 million in 2024, then rose by 21.58% to $4.7 million in 2025, then decreased by 17.82% to $3.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.9 million, $4.7 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.